Searched for
ALZUMAB
Fresh tailwinds emerge as government comes in again with intent: 7 pharma stocks with upside potential of up to 36%- Ignore noise on the street, stick to basics: 5 stocks from different sectors with an upside potential of up to 38%
- Getting back into shape? 6 Indian pharma stocks with upside potential of up to 41%
- Nifty healthcare index stocks analysts suggest buying have potential upside of more than 19%Except for a pocket in which demand for covid drugs led to sharp surge in pharma stocks, the pharma sector had been under pressure for a lo...10 May, 2023, 01.13 PM IST
- Should you stick to largecaps amid volatile Nifty? These 4 stocks have up to 30% upside scopeAs volatility increases, the focus in the market is shifting to stocks which are considered as relatively defensive. These stocks tend to f...09 Feb, 2023, 05.54 PM IST
- Biocon Q2 results: Net profit drops 22% on higher R&D cost; revenue jumps 10%Biocon reported a 10% rise in total revenue to Rs 1,760 crore driven by overall growth in generics, biosimilar and research services busine...23 Oct, 2020, 09.57 AM IST
- Health ministry decides against including Itolizumab in clinical management protocols for COVID-19The permission to market the drug was granted for the treatment of cytokine release syndrome in 'moderate' to 'severe' Acute Respiratory Di...26 Jul, 2020, 09.23 PM IST
- Biocon to launch drug for COVID-19 patients; priced at Rs 8,000 per vialNew Delhi, Jul 13 () Biotechnology major Biocon on Monday said it will launch biologic drug Itolizumab for the treatment of moderate to sev...13 Jul, 2020, 08.14 PM IST
- Biocon’s biosimilar for treating Covid-19: Patients responded positively, says Kiran Mazumdar-ShawThe Drug Controller General of India (DGCI) has permitted the Bengaluru-headquartered drug maker to market Itolizumab (ALZUMab) injection 2...12 Jul, 2020, 02.55 PM IST
- Biocon gets DCGI nod to use Itolizumab in moderate to severe Covid-19 patientsBiocon said the approval is based on the results from the successful conclusion of a randomized, controlled clinical trial at multiple hosp...11 Jul, 2020, 05.12 PM IST
- Biocon extends licensing pact with Equillium for itolizumabItolizumab, a first-in-class humanized anti-CD6 monoclonal antibody, is developed by Biocon and launched in 2013 in India under the brand n...12 Dec, 2019, 08.13 PM IST
- Our Malaysia facility is focussed on insulin & insulin analogues: Kiran Mazumdar Shaw, BioconIt is likely to take some time before we can actually start very aggressively marketing globally from the Malaysia facility.26 Apr, 2014, 04.44 PM IST
- Small molecule, API biz to be growth drivers for company: Kiran Mazumdar Shaw, Biocon"We have focused on creating key growth drivers and have structured the company along those growth drivers," says Kiran Mazumdar Shaw.22 Aug, 2013, 02.26 PM IST
- Biocon rolls out its first biologic drug for the treatment of psoriasisCalled ALZUMAb, it took 10 years in the making and "is recognition of innovation done by research and development wing of Biocon," said Kir...11 Aug, 2013, 02.41 AM IST
- Biocon seeking partners to develop, market psoriasis drugBiotechnology major Biocon today said it is looking for partners to develop and market its novel biologic drug Itolizumab05 Jun, 2013, 04.58 PM IST
- Biocon to launch psoriasis drug novel biologic in JulyThe company had received marketing authorisation for Itolizumab from the Drugs Controller General of India (DCGI) in January, 2013.28 Apr, 2013, 11.39 AM IST
- Biocon's December quarter performance fails to enthuse the streetBiocon logged a modest performance for the quarter ended December with net sales growth of 23% to Rs 634.2 crore and operating profit growt...25 Jan, 2013, 07.06 PM IST
- Biocon eyes Rs 100 cr from psoriasis drug in next four yearsThe product would be manufactured and formulated as an infusion drug at Biocon's biopharma manufacturing facility at Biocon Park, Bangalore.25 Jan, 2013, 02.31 PM IST
- Biocon gets approval to market anti-psoriasis drug Itolizumab by DCGIThe company said the approval paved the way for the launch of the product, under the brand name Alzumab.09 Jan, 2013, 06.04 AM IST
- Biocon gets DCGI approval to market anti-psoriasis drug, Itolizumab"The company has received market authorisation from the DCGI for its novel biologic Itolizumab, for treatment of chronic plaque psoriasis,"...08 Jan, 2013, 02.27 PM IST
Load More
